Literature DB >> 28890991

Comments on: "Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension".

Nuggehally R Srinivas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28890991     DOI： 10.1007/s13318-017-0432-z

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN： 0378-7966            Impact factor:   2.441


× No keyword cloud information.
  13 in total

1.  Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

Authors:  Kazutaka Yoshihara; Yuying Gao; Hiroshi Shiga; D Russell Wada; Masafumi Hisaoka
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.

Authors:  Kazunori Yoshida; Masahiro Kohzuki
Journal:  Cardiovasc Drug Rev       Date:  2004

3.  OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.

Authors:  Rie Nakagomi-Hagihara; Daisuke Nakai; Kenji Kawai; Yasushi Yoshigae; Taro Tokui; Takaaki Abe; Toshihiko Ikeda
Journal:  Drug Metab Dispos       Date:  2006-02-24       Impact factor: 3.922

4.  Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.

Authors:  Devender Kodati; Harish Kaushik Kotakonda; Narsimhareddy Yellu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

5.  Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil.

Authors:  K von Bergmann; P Laeis; K Püchler; T Sudhop; L R Schwocho; L Gonzalez
Journal:  J Hypertens Suppl       Date:  2001-06

6.  Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.

Authors:  Tomoko Ishizuka; Izumi Fujimori; Atsuko Nishida; Hidetaka Sakurai; Yasushi Yoshigae; Kaori Nakahara; Atsushi Kurihara; Toshihiko Ikeda; Takashi Izumi
Journal:  Drug Metab Dispos       Date:  2011-11-15       Impact factor: 3.922

7.  Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure.

Authors:  Seiko Endo; Aiko Fukahori; Shinya Tokuhiro; Akira Shinagawa; Joseph Walker; Kazutaka Yoshihara; Hitoshi Ishizuka; Ichiro Ieiri; Yuichi Sugiyama
Journal:  J Hum Genet       Date:  2012-06-14       Impact factor: 3.172

8.  Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships.

Authors:  Xinning Yang; Yash A Gandhi; David B Duignan; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-11       Impact factor: 4.009

9.  Interindividual variability of carboxymethylenebutenolidase homolog, a novel olmesartan medoxomil hydrolase, in the human liver and intestine.

Authors:  Tomoko Ishizuka; Veronika Rozehnal; Thomas Fischer; Ayako Kato; Seiko Endo; Yasushi Yoshigae; Atsushi Kurihara; Takashi Izumi
Journal:  Drug Metab Dispos       Date:  2013-03-07       Impact factor: 3.922

10.  Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.

Authors:  Hyerang Roh; Hankil Son; Donghwan Lee; HeeChul Chang; Chohee Yun; Kyungsoo Park
Journal:  Clin Ther       Date:  2014-07-10       Impact factor: 3.393
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.